Cargando…

Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab

A novel combination of capecitabine, oxaliplatin, and bevacizumab was evaluated in colorectal cancer patients enrolled in a phase II clinical trial. In this retrospective analysis, plasma samples from patients receiving capecitabine, oxaliplatin, and bevacizumab were analyzed to investigate biomarke...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Yingmiao, Starr, Mark D, Bulusu, Anuradha, Pang, Herbert, Wong, Nan Soon, Honeycutt, Wanda, Amara, Anthony, Hurwitz, Herbert I, Nixon, Andrew B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2013
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3639662/ https://www.ncbi.nlm.nih.gov/pubmed/23634291 http://dx.doi.org/10.1002/cam4.71

Ejemplares similares

Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer
por: Bazarbashi, Shouki, et al.
Publicado: (2015)

A phase I study of ABT-510 plus bevacizumab in advanced solid tumors
por: Uronis, Hope E, et al.
Publicado: (2013)

Effects of the combination of TRC105 and bevacizumab on endothelial cell biology
por: Liu, Yingmiao, et al.
Publicado: (2014)

Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis
por: Buchler, Tomas, et al.
Publicado: (2014)

Relapsed urachal carcinoma responding to first‐line chemotherapy with capecitabine‐oxaliplatin plus bevacizumab
por: Hatano, Akihiko, et al.
Publicado: (2023)

Bevacizumab Combined With Oxaliplatin/Capecitabine in Patient With Refractory and Recurrent Mucinous Adenocarcinoma of the Appendix: A Case Report
por: Liu, Wenzhi, et al.
Publicado: (2019)

Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma
por: Vithayathil, Mathew, et al.
Publicado: (2022)

First-line bevacizumab and capecitabine–oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study
por: Feliu, J, et al.
Publicado: (2014)

Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer
por: Dellas, Kathrin, et al.
Publicado: (2013)

Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
por: Bang, Yeong Hak, et al.
Publicado: (2021)

Modulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancer
por: Liu, Yingmiao, et al.
Publicado: (2014)

Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial
por: Mettu, Niharika B., et al.
Publicado: (2022)

Diffuse Alveolar Hemorrhage in a Patient Receiving Bevacizumab for Lung Cancer
por: Sethi, Sakshi, et al.
Publicado: (2014)

Tissue MicroRNAs as Predictors of Outcome in Patients with Metastatic Colorectal Cancer Treated with First Line Capecitabine and Oxaliplatin with or without Bevacizumab
por: Boisen, Mogens K., et al.
Publicado: (2014)

Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205
por: Hoehler, T, et al.
Publicado: (2013)

Capecitabine and oxaliplatin combined with bevacizumab are feasible for treating selected Japanese patients at least 75 years of age with metastatic colorectal cancer
por: Munemoto, Yoshinori, et al.
Publicado: (2015)

Blood‐based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance)
por: Hatch, Ace J., et al.
Publicado: (2016)

Economic comparison of capecitabine + oxaliplatin and 5-fluorouracil + oxaliplatin in the adjuvant treatment of colon cancer
por: Aitini, Enrico, et al.
Publicado: (2012)

Prevention of oxaliplatin-related neurotoxicity by ω-3 PUFAs: A double-blind randomized study of patients receiving oxaliplatin combined with capecitabine for colon cancer
por: Zhang, Xinjie, et al.
Publicado: (2020)

Clusterin role in hepatocellular carcinoma patients treated with oxaliplatin
por: Wang, Xiumei, et al.
Publicado: (2020)

Timing of chemotherapy‐induced neutropenia is a prognostic factor in patients with advanced gastric cancer undergoing first‐line chemotherapy with oxaliplatin and capecitabine: a retrospective study
por: Wang, Yanrong, et al.
Publicado: (2018)

Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model
por: Iwai, Toshiki, et al.
Publicado: (2016)

Retrospective study of preoperative chemoradiotherapy with capecitabine versus capecitabine plus oxaliplatin for locally advanced rectal cancer
por: Yang, Xiao-Hui, et al.
Publicado: (2020)

Capecitabine Plus Oxaliplatin Combination Therapy for Basal Cell Carcinoma
por: Rhee, Jiyoung, et al.
Publicado: (2019)

Pilot investigation of circulating angiogenic and inflammatory biomarkers associated with vascular malformations
por: Wetzel-Strong, Sarah E., et al.
Publicado: (2021)

Phase I/II Study of Capecitabine Plus Oxaliplatin (XELOX) Plus Bevacizumab As First-line Therapy in Japanese Patients with Metastatic Colorectal Cancer
por: Doi, Toshihiko, et al.
Publicado: (2010)

Dose-intense capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: a multi-centre phase II study
por: Jackson, Christopher GCA, et al.
Publicado: (2014)

A case of advanced intrahepatic cholangiocarcinoma accidentally, but successfully, treated with capecitabine plus oxaliplatin (CAPOX) therapy combined with bevacizumab: a case report
por: Uji, Masahito, et al.
Publicado: (2016)

Neoadjuvant oxaliplatin and capecitabine combined with bevacizumab plus radiotherapy for locally advanced rectal cancer: results of a single-institute phase II study
por: Yu, Xin, et al.
Publicado: (2018)

Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial
por: Madi, A, et al.
Publicado: (2012)

Toxicity associated with capecitabine plus oxaliplatin in colorectal cancer before and after an institutional policy of capecitabine dose reduction
por: Baird, R, et al.
Publicado: (2011)

Cost-effectiveness analysis of capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer
por: Peng, Jingyuan, et al.
Publicado: (2018)

Identification of transcriptome signature for predicting clinical response to bevacizumab in recurrent glioblastoma
por: Choi, Seung Won, et al.
Publicado: (2018)

Prognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer (CRC) receiving bevacizumab*
por: Price, Timothy J, et al.
Publicado: (2013)

Microvascular density assessed by CD31 predicts clinical benefit upon bevacizumab treatment in metastatic colorectal cancer: results of the PassionATE study, a translational prospective Phase II study of capecitabine and irinotecan plus bevacizumab followed by capecitabine and oxaliplatin plus bevacizumab or the reverse sequence in patients in mCRC
por: Bianconi, Daniela, et al.
Publicado: (2020)

Genome Wide Association Study for Predictors of Progression Free Survival in Patients on Capecitabine, Oxaliplatin, Bevacizumab and Cetuximab in First-Line Therapy of Metastatic Colorectal Cancer
por: Pander, Jan, et al.
Publicado: (2015)

Combination of Capecitabine and Oxaliplatin is an Effective Treatment Option for Advanced Neuroendocrine Tumors
por: Ferrarotto, Renata, et al.
Publicado: (2013)

Postoperative Chemoradiotherapy With Capecitabine and Oxaliplatin vs Capecitabine for Stage II to III Rectal Cancer: A Randomized Clinical Trial
por: Li, Ning, et al.
Publicado: (2021)

Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first‐line treatment for metastatic colorectal cancer: Safety lead‐in results from the QUATTRO-II study
por: Kotani, Daisuke, et al.
Publicado: (2021)

Neoadjuvant Capecitabine and Oxaliplatin Before Concurrent Capecitabine and Radiation in Locally Advanced Rectal Cancers: Experience of a Cancer Hospital in Pakistan
por: Mansha, Muhammad Atif, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_e4097fm66ut1gnatq645uhkhj0